Literature DB >> 11166014

Human kallikrein 6 as a biomarker of alzheimer's disease.

E P Diamandis1, G M Yousef, C Petraki, A R Soosaipillai.   

Abstract

OBJECTIVES: Alzheimer's disease (AD) is a major cause of dementia in the elderly. It is generally difficult to diagnose accurately early AD. A few biomarkers, including tau protein and amyloid beta-42, are now used as aids for diagnosis and monitoring of AD. Our aim was to examine the possible use of cerebrospinal fluid, blood and tissue, and human kallikrein 6 (hK6) concentration as a marker of AD.
METHODS: We have used a highly sensitive and specific immunofluorometric procedure for measuring hK6. We measured hK6 in tissue extracts from AD brain or normal individuals, in cerebrospinal fluids of AD patients or normals and in whole blood of AD patients and normals and compared the findings. We have used ten pairs of AD/normal controls in all cases.
RESULTS: We found that hK6 concentration is tissue extracts from AD brain were approximately twofold lower than extracts from normal controls. Further, we found that cerebrospinal fluid hK6 concentration is approximately a threefold increase, in comparison to cerebrospinal fluid controls (p = 0.001). We have also found that the whole blood hK6 concentration in AD patients is about ten times higher than hK6 concentration in normal controls (p = 0.002). We have immunohistochemically localized the expression of hK6 in epithelial cells of the chorioid plexus.
CONCLUSIONS: This is the first report describing significant elevations of cerebrospinal fluid and plasma and whole blood hK6 concentration in AD patients, in comparison to controls. These data suggest that hK6 may constitute a new biomarker for diagnosis and monitoring of AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11166014     DOI: 10.1016/s0009-9120(00)00185-5

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  22 in total

1.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

Review 2.  What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders?

Authors:  Maria da Graça Naffah-Mazzacoratti; Telma Luciana Furtado Gouveia; Priscila Santos Rodrigues Simões; Sandra Regina Perosa
Journal:  World J Biol Chem       Date:  2014-05-26

3.  Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis.

Authors:  Samantha Kimball; Reinhold Vieth; Hans-Michael Dosch; Amit Bar-Or; Roy Cheung; Donald Gagne; Paul O'Connor; Cheryl D'Souza; Melanie Ursell; Jodie M Burton
Journal:  J Clin Endocrinol Metab       Date:  2011-06-22       Impact factor: 5.958

4.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Authors:  Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

5.  Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms.

Authors:  Hyesook Yoon; Maja Radulovic; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2018-09-25       Impact factor: 3.915

6.  The autolytic regulation of human kallikrein-related peptidase 6.

Authors:  Sachiko I Blaber; Hyesook Yoon; Isobel A Scarisbrick; Maria Aparecida Juliano; Michael Blaber
Journal:  Biochemistry       Date:  2007-04-07       Impact factor: 3.162

7.  DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease.

Authors:  Xiangmin Lin; Travis J Cook; Cyrus P Zabetian; James B Leverenz; Elaine R Peskind; Shu-Ching Hu; Kevin C Cain; Catherine Pan; John Scott Edgar; David R Goodlett; Brad A Racette; Harvey Checkoway; Thomas J Montine; Min Shi; Jing Zhang
Journal:  Sci Rep       Date:  2012-12-11       Impact factor: 4.379

8.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

9.  Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.

Authors:  Malin Wennström; Yulia Surova; Sara Hall; Christer Nilsson; Lennart Minthon; Fredrik Boström; Oskar Hansson; Henrietta M Nielsen
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

10.  Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Evangelia Prosnikli; Gregory P Evangelatos; Evangelia Livaniou
Journal:  Chem Cent J       Date:  2012-12-05       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.